8-K: Henry Schein Reports Strong Q2 2026, Raises FY2026 Guidance

Henry Schein announced robust second-quarter 2026 financial results, exceeding prior expectations and leading to an upward revision of its full-year 2026 financial guidance.

Summary

• Henry Schein reported strong financial results for the second quarter ended June 27, 2026.
• Total net sales increased by 6.7% to $3.5 billion compared to the second quarter of 2025.
• GAAP diluted EPS was $0.82, up from $0.70 in Q2 2025.
• Non-GAAP diluted EPS was $1.27, an increase from $1.10 in Q2 2025.
• Adjusted EBITDA for the quarter was $288 million, up from $256 million in Q2 2025.
• The company raised its full-year 2026 guidance, projecting non-GAAP diluted EPS between $5.29 and $5.39.
• Full-year 2026 sales growth is now expected to be between 4.5% and 5.5%.
• Adjusted EBITDA growth for FY2026 is projected to be in the mid to high-single digits.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive report, with strong performance in the second quarter and an optimistic outlook for the full year, including raised guidance.

Positives

• Strong second-quarter sales performance with a 6.7% increase to $3.5 billion.
• Accelerated internal local currency sales growth compared to the first quarter.
• Improved gross margins contributing to strong earnings growth.
• Raised full-year 2026 guidance for non-GAAP diluted EPS, sales growth, and Adjusted EBITDA growth.
• Repurchased approximately 2.6 million shares of common stock for $200 million in Q2 2026.
• Sustained momentum across businesses and solid operational execution highlighted by the CEO.
• Value creation initiatives are showing early benefits and are on track to achieve goals.

Negatives

• Restructuring and related costs were $29 million in Q2 2026, an increase from $23 million in Q2 2025.
• Operating expenses, specifically Selling, general and administrative costs, increased to $831 million from $778 million.
• The company is unable to provide a reconciliation of its 2026 non-GAAP diluted EPS guidance to GAAP EPS due to the uncertainty of restructuring expenses.

Risks

• Dependence on third parties for product manufacture and supply.
• Risks related to achieving strategic growth objectives and value creation initiatives.
• Potential for cyberattacks or other privacy or data security breaches.
• Highly competitive and consolidating market, including competition from online commerce sites.
• Political, economic, and regulatory influences on the healthcare industry.
• Supply chain disruptions and increases in shipping and energy costs.
• Changes in laws and policies governing international trade, tariffs, and sanctions.
• Geopolitical risks including war, terrorism, and public unrest.

Future Outlook

The company has raised its full-year 2026 guidance, now expecting non-GAAP diluted EPS between $5.29 and $5.39, total sales growth of 4.5% to 5.5%, and Adjusted EBITDA growth in the mid to high-single digits. This guidance assumes foreign currency exchange rates remain generally consistent with current levels and does not include certain adjustments like restructuring expenses.

Management Comments

• "We delivered strong sales performance and margin improvement in the second quarter, driven by sustained momentum across our businesses and solid operational execution by the team."
• "Our first-half performance and the sustained momentum have positioned us to raise our FY2026 guidance."
• "Our value creation plans remain a top focus for our team, and we are on track to achieve our goals."
• "As we sharpen our focus, our priorities ahead are accelerating growth, simplifying our business, driving operational rigor, and further deepening our customer relationships, all of which we believe will create sustainable shareholder value."

Industry Context

StockSavvy.ai notes that Henry Schein's performance in the healthcare solutions sector, particularly for office-based practitioners, appears robust. The company's ability to drive internal sales growth and improve margins, even amidst a competitive landscape, suggests effective strategic execution and market positioning.

Stakeholder Impact

• Shareholders: Positive impact due to raised guidance, increased EPS, and ongoing share repurchases, suggesting potential for increased shareholder value.
• Customers: Continued provision of essential healthcare solutions and potential for improved operational efficiency through the company's offerings.
• Employees: Implied positive impact through solid operational execution and focus on deepening customer relationships, potentially leading to business stability and growth.

Next Steps

• Continue to focus on accelerating growth, simplifying the business, driving operational rigor, and deepening customer relationships.
• Achieve goals related to value creation plans.
• Monitor foreign currency exchange rates for their impact on guidance.

Key Dates

Recommendation

The raised guidance and strong Q2 results are positive, but the company faces ongoing risks in a competitive market. While performance is improving, a 'hold' recommendation reflects a balanced view of current strengths and potential headwinds, pending further execution of strategic initiatives.

Keywords

healthcare solutions, dental practitioners, medical practitioners, financial results, sales growth, earnings per share, Adjusted EBITDA, guidance